This “Binge-eating disorder - Pipeline Insight, 2021” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Binge eating disorder (BED) is a mental illness characterised by regular episodes of binge eating. Binge eating involves eating an excessive amount of food, which may take place in a rapid space of time, or may be more of an extended grazing. These episodes can feel chaotic, uncontrollable and highly distressing. During a binge eating episode, a person may not be hungry, but may continue to eat past the point of feeling comfortably full. It is common for people to binge eat alone or in secret, and experience intense feelings of guilt, shame, disgust and low mood after a binge. A binge is different from overeating and is far more pervasive. It is the intense drive to overeat which is experienced again and again over time, accompanied by feelings of shame, guilt and feeling out of control.
"Binge-eating disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-eating disorder pipeline landscape is provided which includes the disease overview and Binge-eating disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-eating disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-eating disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Binge-eating disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-eating disorder.
This segment of the Binge-eating disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
SEP-225289 is a dopamine and norepinephrine reuptake inhibitor (DNRI). SEP-225289 has an extended half-life (47-77 hours) that supports the potential for plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.
ACT-539313 is an Orexin receptor type 1 antagonist being developed by Idorsia Pharmaceuticals. Currently, it is in Phase II stage of clinical trial evaluation to treat Binge-eating disorder.
This segment of the report provides insights about the different Binge-eating disorder drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 4+ key companies which are developing the therapies for Binge-eating disorder. The companies which have their Binge-eating disorder drug candidates in the most advanced stage, i.e. phase II include, Idorsia Pharmaceuticals.
This report covers around 4+ products under different phases of clinical development like
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Binge-eating disorder therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-eating disorder drugs.
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Binge-eating disorder Understanding
Binge-eating disorder: Overview
Binge eating disorder (BED) is a mental illness characterised by regular episodes of binge eating. Binge eating involves eating an excessive amount of food, which may take place in a rapid space of time, or may be more of an extended grazing. These episodes can feel chaotic, uncontrollable and highly distressing. During a binge eating episode, a person may not be hungry, but may continue to eat past the point of feeling comfortably full. It is common for people to binge eat alone or in secret, and experience intense feelings of guilt, shame, disgust and low mood after a binge. A binge is different from overeating and is far more pervasive. It is the intense drive to overeat which is experienced again and again over time, accompanied by feelings of shame, guilt and feeling out of control.
"Binge-eating disorder - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Binge-eating disorder pipeline landscape is provided which includes the disease overview and Binge-eating disorder treatment guidelines. The assessment part of the report embraces, in depth Binge-eating disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Binge-eating disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Binge-eating disorder R&D. The therapies under development are focused on novel approaches to treat/improve Binge-eating disorder.
Binge-eating disorder Emerging Drugs Chapters
This segment of the Binge-eating disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Binge-eating disorder Emerging Drugs
SEP-225289: Sumitomo Dainippon Pharma
SEP-225289 is a dopamine and norepinephrine reuptake inhibitor (DNRI). SEP-225289 has an extended half-life (47-77 hours) that supports the potential for plasma concentrations yielding a continuous therapeutic effect over the 24-hour dosing interval.
ACT-539313: Idorsia Pharmaceuticals
ACT-539313 is an Orexin receptor type 1 antagonist being developed by Idorsia Pharmaceuticals. Currently, it is in Phase II stage of clinical trial evaluation to treat Binge-eating disorder.
Binge-eating disorder: Therapeutic Assessment
This segment of the report provides insights about the different Binge-eating disorder drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Binge-eating disorder
There are approx. 4+ key companies which are developing the therapies for Binge-eating disorder. The companies which have their Binge-eating disorder drug candidates in the most advanced stage, i.e. phase II include, Idorsia Pharmaceuticals.
Phases
This report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Binge-eating disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Binge-eating disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Binge-eating disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Binge-eating disorder drugs.
Binge-eating disorder Report Insights
- Binge-eating disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Binge-eating disorder Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Binge-eating disorder drugs?
- How many Binge-eating disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Binge-eating disorder?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Binge-eating disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Binge-eating disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Sumitomo Dainippon Pharma
- Idorsia Pharmaceuticals
- Takeda
- Bright Minds Biosciences
- Praxis Bioresearch
Key Products
- SEP-225289
- ACT-539313
- Vortioxetine
- BMB-101
- PRX-P4-003
Table of Contents
IntroductionExecutive Summary
Binge-eating disorder: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Binge-eating disorder - Analytical Perspective
Late Stage Products (Preregistration)
- Comparative Analysis
SEP-225289: Sumitomo Dainippon Pharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
ACT-539313: Idorsia Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
BMB-101: Bright Minds Biosciences
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Binge-eating disorder Key Companies
Binge-eating disorder Key Products
Binge-eating disorder- Unmet Needs
Binge-eating disorder- Market Drivers and Barriers
Binge-eating disorder- Future Perspectives and Conclusion
Binge-eating disorder Analyst Views
Binge-eating disorder Key Companies
AppendixList of Tables
Table 1 Total Products for Binge-eating disorder
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Binge-eating disorder
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Sumitomo Dainippon Pharma
- Idorsia Pharmaceuticals
- Takeda
- Bright Minds Biosciences
- Praxis Bioresearch
